Your browser doesn't support javascript.
loading
Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women.
Hu, Yue-Mei; Guo, Meng; Li, Chang-Gui; Chu, Kai; He, Wen-Gang; Zhang, Jing; Gu, Jian-Xiang; Li, Juan; Zhao, Hui; Wu, Xiang-Hong; Lin, BiZhen; Lin, Zhi-Jie; Yao, Xing-Mei; Li, Ya-Fei; Wei, FeiXue; Huang, Yue; Su, Ying-Ying; Zhu, Feng-Cai; Huang, Shou-Jie; Pan, Hui-Rong; Wu, Ting; Zhang, Jun; Xia, Ning-Shao.
Afiliação
  • Hu YM; Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
  • Guo M; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University, Xiamen, 361102, China.
  • Li CG; National Institute for Food and Drug Control, Beijing, 102629, China.
  • Chu K; Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
  • He WG; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University, Xiamen, 361102, China.
  • Zhang J; Sheyang Center for Disease Control and Prevention, Sheyang, 244300, China.
  • Gu JX; Sheyang Center for Disease Control and Prevention, Sheyang, 244300, China.
  • Li J; National Institute for Food and Drug Control, Beijing, 102629, China.
  • Zhao H; National Institute for Food and Drug Control, Beijing, 102629, China.
  • Wu XH; Sheyang Center for Disease Control and Prevention, Sheyang, 244300, China.
  • Lin B; Xiamen Innovax Biotech Company, Xiamen, 361022, China.
  • Lin ZJ; Xiamen Innovax Biotech Company, Xiamen, 361022, China.
  • Yao XM; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University, Xiamen, 361102, China.
  • Li YF; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University, Xiamen, 361102, China.
  • Wei F; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University, Xiamen, 361102, China.
  • Huang Y; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University, Xiamen, 361102, China.
  • Su YY; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University, Xiamen, 361102, China.
  • Zhu FC; Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
  • Huang SJ; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University, Xiamen, 361102, China.
  • Pan HR; Xiamen Innovax Biotech Company, Xiamen, 361022, China.
  • Wu T; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University, Xiamen, 361102, China.
  • Zhang J; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University, Xiamen, 361102, China. zhangj@xmu.edu.cn.
  • Xia NS; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University, Xiamen, 361102, China. nsxia@xmu.edu.cn.
Sci China Life Sci ; 63(4): 582-591, 2020 Apr.
Article em En | MEDLINE | ID: mdl-31231780
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra Escherichia coli / Infecções por Papillomavirus / Papillomavirus Humano 16 / Papillomavirus Humano 18 / Vacinas contra Papillomavirus Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Child / Female / Humans País/Região como assunto: Asia Idioma: En Revista: Sci China Life Sci Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China País de publicação: China
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra Escherichia coli / Infecções por Papillomavirus / Papillomavirus Humano 16 / Papillomavirus Humano 18 / Vacinas contra Papillomavirus Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Child / Female / Humans País/Região como assunto: Asia Idioma: En Revista: Sci China Life Sci Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China País de publicação: China